In November, the Boston-based biotech firm Karuna Therapeutics submitted its new schizophrenia medication, called KarXT, to the US Food and Drug Administration for approval. If the agency gives KarXT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback